As per FDA approval in 2021, it's indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes mellitus or high cholesterol (hyperlipidemia)
The recent rise in off-label use of semaglutide, particularly Ozempic, has led to drug shortages in several countries, including the United States, Canada, and Australia
This study was published in 2008
Zepbound was approved a year and a half later, in November 2023, for chronic weight management in adults with obesity as well as those who are overweight and have at least one weight-related condition (like high blood pressure or high cholesterol)
Safety Signals to Discuss Before Any Combination Combining medicines that reduce appetite can raise concerns about tolerability, hydration, and adequate nutrition
A.MarczinskiC